drugset / Trial / NCT00522795
Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)
Phase 2
Completed
40 enrolled
Brown University
University of Maryland Greenebaum Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
Timeline
- Start
- 2007-08
- Primary completion
- 2010-02
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | paclitaxel poliglumex | Other / unclassified | 50 mg/m2 | Intravenous |